Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 21, 2026, 11:24 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–4 of 4 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Blastomycosis Clear all
Completed Phase 3 Interventional

A Randomized, Open, Comparative Multicenter Study of Initial Treatment With Intravenous Itraconazole Versus Amphotericin B Followed by Consolidation Treatment With Itraconazole Capsules in Patients With Blastomycosis or Histoplasmosis

NCT00002159
View directory record Official record
Conditions
HIV Infections, Histoplasmosis, Blastomycosis
Interventions
Itraconazole, Amphotericin B
Drug
Lead sponsor
Janssen, LP
Industry
Eligibility
13 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
9
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Atlanta, Georgia + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Jul 21, 2026, 11:24 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Endemic Mycoses Treatment With SUBA-itraconazole vs Itraconazole

NCT03572049
View directory record Official record
Conditions
Invasive Fungal Infections
Interventions
SUBA itraconazole, Conventional itraconazole
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
19 Years and older
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
11
States / cities
Birmingham, Alabama • Tucson, Arizona • Sacramento, California + 7 more
Source: ClinicalTrials.gov public record
Updated Jul 6, 2023 · Synced Jul 21, 2026, 11:24 AM EDT
Completed Phase 3 Interventional Results available

Study to Evaluate the Efficacy and Safety of Ibrexafungerp in Patients With Fungal Diseases That Are Refractory to or Intolerant of Standard Antifungal Treatment

NCT03059992
View directory record Official record
Conditions
Invasive Candidiasis, Mucocutaneous Candidiasis, Coccidioidomycosis, Histoplasmosis, Blastomycosis, Chronic Pulmonary Aspergillosis, Allergic Bronchopulmonary Aspergillosis, Invasive Pulmonary Aspergillosis, Recurrent Vulvovaginal Candidiasis, Other Emerging Fungi
Interventions
Ibrexafungerp
Drug
Lead sponsor
Scynexis, Inc.
Industry
Eligibility
18 Years and older
Enrollment
233 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
20
States / cities
Birmingham, Alabama • Sacramento, California • San Francisco, California + 16 more
Source: ClinicalTrials.gov public record
Updated Nov 19, 2024 · Synced Jul 21, 2026, 11:24 AM EDT
Completed No phase listed Observational

Evaluation of the Association of Polymorphisms in the Innate Immune System With the Risk for Blastomycosis Dermatitidis Infection in Patients Not Infected With HIV and Complications Associated With Blastomycosis Dermatitidis Infection

NCT00001702
View directory record Official record
Conditions
Blastomycosis
Interventions
Not listed
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Not listed
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1998
U.S. locations
2
States / cities
Birmingham, Alabama • Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 1, 2017 · Synced Jul 21, 2026, 11:24 AM EDT